Kouros Owzar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3995041/publications.pdf

Version: 2024-02-01

73 papers

1,625 citations

331670 21 h-index 330143 37 g-index

76 all docs 76 docs citations

76 times ranked 4208 citing authors

#	Article	IF	CITATIONS
1	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	21.4	294
2	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. Journal of Clinical Oncology, 2015, 33, 4167-4175.	1.6	149
3	Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radical Biology and Medicine, 2008, 44, 982-989.	2.9	111
4	A Genome-Wide Association Study of Overall Survival in Pancreatic Cancer Patients Treated with Gemcitabine in CALGB 80303. Clinical Cancer Research, 2012, 18, 577-584.	7.0	91
5	Identification of a DNA Damage–Induced Alternative Splicing Pathway That Regulates p53 and Cellular Senescence Markers. Cancer Discovery, 2017, 7, 766-781.	9.4	70
6	Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy. Nature Communications, 2020, 11, 6410.	12.8	66
7	A Novel Genetic Variant in Long Non-coding RNA Gene NEXN-AS1 is Associated with Risk of Lung Cancer. Scientific Reports, 2016, 6, 34234.	3.3	48
8	Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma. JCI Insight, 2019, 4, .	5.0	47
9	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood, 2017, 130, 2131-2145.	1.4	37
10	Power and Sample Size Calculations for SNP Association Studies With Censored Timeâ€ŧoâ€Event Outcomes. Genetic Epidemiology, 2012, 36, 538-548.	1.3	30
11	MicroRNA Expression Differentiates Squamous Epithelium from Barrett's Esophagus and Esophageal Cancer. Digestive Diseases and Sciences, 2013, 58, 3178-3188.	2.3	30
12	Post-Irradiation Treatment with a Superoxide Dismutase Mimic, MnTnHex-2-PyP5+, Mitigates Radiation Injury in the Lungs of Non-Human Primates after Whole-Thorax Exposure to Ionizing Radiation. Antioxidants, 2018, 7, 40.	5.1	30
13	Statistical Considerations for Analysis of Microarray Experiments. Clinical and Translational Science, 2011, 4, 466-477.	3.1	28
14	25-Hydroxyvitamin D Levels and Survival in Advanced Pancreatic Cancer: Findings From CALGB 80303 (Alliance). Journal of the National Cancer Institute, 2014, 106, .	6.3	28
15	Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence. Nature Communications, 2020, 11, 5017.	12.8	28
16	Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemotherapy and Pharmacology, 2014, 74, 927-938.	2.3	27
17	Robust rat pulmonary radioprotection by a lipophilic Mn N-alkylpyridylporphyrin, MnTnHex-2-PyP5+. Redox Biology, 2014, 2, 400-410.	9.0	27
18	Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma. Gynecologic Oncology, 2015, 139, 23-29.	1.4	27

#	Article	IF	CITATIONS
19	Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci. Pharmacogenetics and Genomics, 2018, 28, 49-55.	1.5	26
20	A multiple testing procedure to associate gene expression levels with survival. Statistics in Medicine, 2005, 24, 3077-3088.	1.6	24
21	<scp>SET</scp> alpha and <scp>SET</scp> beta <scp>mRNA</scp> isoforms in chronic lymphocytic leukaemia. British Journal of Haematology, 2019, 184, 605-615.	2.5	24
22	Plasmonic nanobiosensors for detection of microRNA cancer biomarkers in clinical samples. Analyst, The, 2020, 145, 4587-4594.	3.5	24
23	Genetic variants in the plateletâ€derived growth factor subunit B gene associated with pancreatic cancer risk. International Journal of Cancer, 2018, 142, 1322-1331.	5.1	20
24	Late effects of total body irradiation on hematopoietic recovery and immune function in rhesus macaques. PLoS ONE, 2019, 14, e0210663.	2.5	20
25	Bloodâ€based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from <scp>CALGB</scp> 80203 (Alliance). Cancer Medicine, 2016, 5, 2249-2260.	2.8	19
26	Apoptotic capacity and risk of squamous cell carcinoma of the head and neck. European Journal of Cancer, 2017, 72, 166-176.	2.8	19
27	p-Value Calculation for Multistage Phase II Cancer Clinical Trials. Journal of Biopharmaceutical Statistics, 2006, 16, 765-775.	0.8	18
28	Functional variants in DCAF4 associated with lung cancer risk in European populations. Carcinogenesis, 2017, 38, 541-551.	2.8	16
29	The Long Noncoding RNA <i>NEAT1</i> Promotes Sarcoma Metastasis by Regulating RNA Splicing Pathways. Molecular Cancer Research, 2020, 18, 1534-1544.	3.4	16
30	Designing phase II studies in cancer with time-to-event endpoints. Clinical Trials, 2008, 5, 209-221.	1.6	14
31	A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. Blood, 2012, 120, 230-230.	1.4	14
32	Pathwayâ€analysis of published genomeâ€wide association studies of lung cancer: A potential role for the <i>CYP4F3</i> locus. Molecular Carcinogenesis, 2017, 56, 1663-1672.	2.7	13
33	The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS ONE, 2018, 13, e0202272.	2.5	13
34	Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033 Journal of Clinical Oncology, 2014, 32, 10508-10508.	1.6	12
35	Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Scientific Reports, 2017, 7, 44634.	3.3	10
36	Genetic variation determines VEGF-A plasma levels in cancer patients. Scientific Reports, 2018, 8, 16332.	3.3	10

3

#	Article	IF	Citations
37	DNA-Damage-Induced Alternative Splicing of p53. Cancers, 2021, 13, 251.	3.7	10
38	Whole-Exome Sequencing of Radiation-Induced Thymic Lymphoma in Mouse Models Identifies Notch1 Activation as a Driver of p53 Wild-Type Lymphoma. Cancer Research, 2021, 81, 3777-3790.	0.9	10
39	A Copula Approach for Detecting Prognostic Genes Associated With Survival Outcome in Microarray Studies. Biometrics, 2007, 63, 1089-1098.	1.4	9
40	Novel genetic variants in the P38MAPK pathway gene <i>ZAK</i> and susceptibility to lung cancer. Molecular Carcinogenesis, 2018, 57, 216-224.	2.7	9
41	Blood-based biomarkers in patients (pts) with metastatic colorectal cancer (mCRC) treated with FOLFOX or FOLFIRI plus bevacizumab (Bev), cetuximab (Cetux), or Bev plus Cetux: Results from CALGB 80405 (Alliance) Journal of Clinical Oncology, 2016, 34, 3597-3597.	1.6	9
42	Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines. Frontiers in Oncology, 2014, 4, 163.	2.8	8
43	Genomeâ€wide association studies of survival in 1520 cancer patients treated with bevacizumabâ€containing regimens. International Journal of Cancer, 2022, 150, 279-289.	5.1	8
44	Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. British Journal of Cancer, 2022, 126, 265-274.	6.4	8
45	Next Generation Distributed Computing for Cancer Research. Cancer Informatics, 2014, 13s7, CIN.S16344.	1.9	7
46	Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). Journal of the National Cancer Institute, 2015, 107, djv188.	6.3	6
47	SparkScore: Leveraging Apache Spark for Distributed Genomic Inference. , 2016, , .		6
48	Reduced mRNA expression of nucleotide excision repair genes in lymphocytes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 2017, 38, 504-510.	2.8	6
49	RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. Lung Cancer, 2021, 153, 90-98.	2.0	6
50	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). Oncologist, 2021, 26, 560-e1103.	3.7	6
51	Comparative analysis of RNA enrichment methods for preparation of <i>Cryptococcus neoformans</i> RNA sequencing libraries. G3: Genes, Genomes, Genetics, 2021, 11, .	1.8	6
52	Obesity and altered angiogenic-related gene expression in endometrial cancer. Gynecologic Oncology, 2021, 163, 320-326.	1.4	5
53	<tt>bcSeq</tt> : an R package for fast sequence mapping in high-throughput shRNA and CRISPR screens. Bioinformatics, 2018, 34, 3581-3583.	4.1	4
54	Single-Cell RNA-Seq Identifies Potentially Pathogenic B Cell Populations That Uniquely Circulate in Patients with Chronic Gvhd. Blood, 2019, 134, 874-874.	1.4	4

#	Article	IF	CITATIONS
55	Differential expression of immune related genes in high-grade ovarian serous carcinoma. Gynecologic Oncology, 2020, 156, 662-668.	1.4	3
56	Predictive accuracy of markers or risk scores for interval censored survival data. Statistics in Medicine, 2020, 39, 2437-2446.	1.6	3
57	Autologous Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieves Outcomes Similar to Allogeneic Transplantation - Results of CALGB 10001 (Alliance). Blood, 2012, 120, 816-816.	1.4	3
58	fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies. BMC Bioinformatics, 2019, 20, 333.	2.6	2
59	Prognostic significance of differential expression of angiogenic genes in women with invasive high-grade serous ovarian carcinoma Journal of Clinical Oncology, 2013, 31, 5509-5509.	1.6	2
60	Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. Prostate Cancer and Prostatic Diseases, 2022, 25, 513-523.	3.9	2
61	HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in <i>RAS</i> -wt advanced colorectal cancer (aCRC) Journal of Clinical Oncology, 2015, 33, 3583-3583.	1.6	1
62	Facilitating the Calculation of the Efficient Score Using Symbolic Computing. American Statistician, 2018, 72, 199-205.	1.6	0
63	An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM) Journal of Clinical Oncology, 2021, 39, 9521-9521.	1.6	0
64	Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study Journal of Clinical Oncology, 2012, 30, 2533-2533.	1.6	0
65	Tumor markers of efficacy and resistance to cetuximab (C) treatment in metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance) Journal of Clinical Oncology, 2013, 31, 11011-11011.	1.6	0
66	Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials Journal of Clinical Oncology, 2013, 31, 6501-6501.	1.6	0
67	A genome-wide association study (GWAS) of docetaxel-induced peripheral neuropathy in CALGB 90401 (Alliance) Journal of Clinical Oncology, 2013, 31, 11053-11053.	1.6	0
68	25-hydroxyvitamin D levels and survival in patients with advanced pancreatic cancer (APC): Findings from CALGB 80303 Journal of Clinical Oncology, 2013, 31, 4022-4022.	1.6	0
69	Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE) Journal of Clinical Oncology, 2014, 32, e16061-e16061.	1.6	0
70	A genome-wide association study (GWAS) of docetaxel-induced neutropenia in CALGB 90401/60404 (Alliance) Journal of Clinical Oncology, 2014, 32, 9612-9612.	1.6	0
71	A genome-wide association study (GWAS) of progression-free survival (PFS) in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503 Journal of Clinical Oncology, 2016, 34, 538-538.	1.6	0
72	The Association of FCGR2A and FCGR3A polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis Journal of Clinical Oncology, 2018, 36, 633-633.	1.6	0

5

#	Article	IF	CITATIONS
73	Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029 Journal of Clinical Oncology, 2019, 37, 587-587.	1.6	O